55 phenotypes from 4 alleles in 7 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Mir146tm1.1Bal/Mir146tm1.1Bal involves: C57BL/6	abnormal bone marrow cell morphology/development	J:173230
	abnormal lymphopoiesis	J:167922
	abnormal regulatory T cell physiology	J:167922
	anemia	J:173230
	decreased erythrocyte cell number	J:173230
	decreased hematocrit	J:173230
	decreased hemoglobin content	J:173230
	decreased interferon-gamma secretion	J:167922
	decreased leukocyte cell number	J:173230
	decreased lymphocyte cell number	J:173230
	decreased monocyte cell number	J:173230
	enlarged spleen	J:173230
	extramedullary hematopoiesis	J:173230
	increased B cell derived lymphoma incidence	J:173230
	increased bone marrow cell number	J:173230
	increased follicular lymphoma incidence	J:173230
	increased myeloid sarcoma incidence	J:173230
	increased regulatory T cell number	J:167922
	increased spleen neoplasm incidence	J:173230
	increased spleen weight	J:173230
	increased T cell derived lymphoma incidence	J:173230
	myelofibrosis	J:173230
	myeloid hyperplasia	J:167922, J:173230
	premature death	J:173230
	thrombocytopenia	J:173230
Mir146tm1.1Bal/Mir146tm1.1Bal involves: C57BL/6 * FVB/N	abnormal immune system physiology	J:173671
	abnormal immune tolerance	J:173671
	abnormal macrophage physiology	J:173671
	abnormal T cell activation	J:173671
	increased circulating interleukin-1 beta level	J:173671
	increased circulating interleukin-6 level	J:173671
	increased circulating interleukin-10 level	J:173671
	increased circulating tumor necrosis factor level	J:173671
	increased interleukin-1 beta secretion	J:173671
	increased interleukin-6 secretion	J:173671
	increased macrophage nitric oxide production	J:173671
	increased susceptibility to bacterial infection induced morbidity/mortality	J:173671
	increased susceptibility to endotoxin shock	J:173671
	increased tumor necrosis factor secretion	J:173671
	myeloid hyperplasia	J:173671
	premature death	J:173671
Mir146tm1.1Lfl/Mir146tm1.1Lfl Ighg1tm1(cre)Cgn/Ighg1+ involves: 129P2/OlaHsd * C57BL/6	increased germinal center B cell number	J:266124
	increased T follicular helper cell number	J:266124
Mir146tm1.1Lfl/Mir146tm1.1Lfl Tg(CD2-icre)4Kio/0 involves: C57BL/6 * C57BL/10 * CBA/Ca	increased germinal center B cell number	J:266124
	increased T follicular helper cell number	J:266124
Mir146tm1.1Lfl/Mir146tm1.1Lfl Tg(Cd4-cre)1Cwi/0 involves: C57BL/6 * DBA/2	normal immune system phenotype	J:266124
Mir146tm1.1Lfl/Mir146tm1.1Lfl Tg(Cr2-cre)3Cgn/0 involves: C57BL/6	increased anti-double stranded DNA antibody level	J:266124
	increased germinal center B cell number	J:266124
	increased IgG1 level	J:266124
	increased IgG level	J:266124
	increased plasma cell number	J:266124
	increased T follicular helper cell number	J:266124
Mir146tm1.1Mtm/Mir146tm1.1Mtm involves: 129P2/OlaHsd * C57BL/6 * FVB	normal mortality/aging	J:181831
Mir146tm2.1Bal/Mir146tm2.1Bal involves: 129S1/Sv * C57BL/6 * FVB/N	abnormal bone marrow cell physiology	J:173671
	abnormal immune system physiology	J:173671
	abnormal immune tolerance	J:173671
	abnormal macrophage physiology	J:173671
	abnormal spleen B cell follicle morphology	J:173671
	abnormal T cell activation	J:173671
	anemia	J:173671
	decreased hematocrit	J:173671
	decreased hemoglobin content	J:173671
	decreased lymphocyte cell number	J:173671
	decreased monocyte cell number	J:173671
	enlarged lymph nodes	J:173671
	enlarged spleen	J:173671
	extramedullary hematopoiesis	J:173671
	normal immune system phenotype	J:173671
	increased acute inflammation	J:173671
	increased anti-double stranded DNA antibody level	J:173671
	increased circulating interleukin-1 beta level	J:173671
	increased circulating interleukin-6 level	J:173671
	increased circulating interleukin-10 level	J:173671
	increased circulating tumor necrosis factor level	J:173671
	increased follicular lymphoma incidence	J:173671
	increased hemolymphoid system tumor incidence	J:173671
	increased interleukin-1 beta secretion	J:173671
	increased interleukin-6 secretion	J:173671
	increased macrophage nitric oxide production	J:173671
	increased spleen germinal center number	J:173671
	increased spleen germinal center size	J:173671
	increased spleen weight	J:173671
	increased susceptibility to bacterial infection induced morbidity/mortality	J:173671
	increased susceptibility to endotoxin shock	J:173671
	increased tumor incidence	J:173671
	increased tumor necrosis factor secretion	J:173671
	myeloid hyperplasia	J:173671
	premature death	J:173671
	thrombocytopenia	J:173671